CN101039686A - 免疫刺激婴儿营养物 - Google Patents
免疫刺激婴儿营养物 Download PDFInfo
- Publication number
- CN101039686A CN101039686A CNA2005800351685A CN200580035168A CN101039686A CN 101039686 A CN101039686 A CN 101039686A CN A2005800351685 A CNA2005800351685 A CN A2005800351685A CN 200580035168 A CN200580035168 A CN 200580035168A CN 101039686 A CN101039686 A CN 101039686A
- Authority
- CN
- China
- Prior art keywords
- alimentation composition
- acid
- component
- nucleotide
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021125 infant nutrition Nutrition 0.000 title description 4
- 230000004936 stimulating effect Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 102
- 239000002773 nucleotide Substances 0.000 claims abstract description 36
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 36
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 12
- 239000002777 nucleoside Substances 0.000 claims abstract description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 11
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 10
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 150000004676 glycans Chemical class 0.000 claims abstract description 9
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims abstract description 6
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 5
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 5
- 239000002157 polynucleotide Substances 0.000 claims abstract description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 47
- 150000002482 oligosaccharides Chemical class 0.000 claims description 47
- 230000002378 acidificating effect Effects 0.000 claims description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 239000011701 zinc Substances 0.000 claims description 14
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- 229920001277 pectin Polymers 0.000 claims description 10
- 235000010987 pectin Nutrition 0.000 claims description 10
- 239000001814 pectin Substances 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 7
- 150000002270 gangliosides Chemical class 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002421 ganglioside group Chemical group 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000010318 polygalacturonic acid Substances 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 abstract description 6
- 210000004251 human milk Anatomy 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 229920000388 Polyphosphate Polymers 0.000 abstract 1
- 125000000309 desoxyribosyl group Chemical class C1(C[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000001205 polyphosphate Substances 0.000 abstract 1
- 235000011176 polyphosphates Nutrition 0.000 abstract 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 34
- 235000021342 arachidonic acid Nutrition 0.000 description 16
- 229940114079 arachidonic acid Drugs 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- 150000004665 fatty acids Chemical class 0.000 description 16
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 15
- 150000002402 hexoses Chemical class 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- -1 phosphate ester Chemical class 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 230000032050 esterification Effects 0.000 description 9
- 238000005886 esterification reaction Methods 0.000 description 9
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 8
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013350 formula milk Nutrition 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 5
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 5
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 229960004232 linoleic acid Drugs 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 150000003904 phospholipids Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 235000020244 animal milk Nutrition 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229940098330 gamma linoleic acid Drugs 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 235000021129 infant diet Nutrition 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003050 macronutrient Effects 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RDPUKVRQKWBSPK-UHFFFAOYSA-N 3-Methylcytidine Natural products O=C1N(C)C(=N)C=CN1C1C(O)C(O)C(CO)O1 RDPUKVRQKWBSPK-UHFFFAOYSA-N 0.000 description 1
- RDPUKVRQKWBSPK-ZOQUXTDFSA-N 3-methylcytidine Chemical compound O=C1N(C)C(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RDPUKVRQKWBSPK-ZOQUXTDFSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- VQUZNVATTCZTQO-UHFFFAOYSA-N D-xyluronic acid Natural products O=CC(O)C(O)C(O)C(O)=O VQUZNVATTCZTQO-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DOTFUZMJSA-N L-Alturonic Acid Chemical compound OC1O[C@@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DOTFUZMJSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- VQUZNVATTCZTQO-HZLVTQRSSA-N O=C[C@H](O)[C@H](O)[C@H](O)C(O)=O Chemical compound O=C[C@H](O)[C@H](O)[C@H](O)C(O)=O VQUZNVATTCZTQO-HZLVTQRSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108010029182 Pectin lyase Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- OLGWXCQXRSSQPO-UHFFFAOYSA-N diguanosine tetraphosphate Natural products C1=NC(C(N=C(N)N2)=O)=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OCC(C(O)C1O)OC1N1C=NC2=C1NC(N)=NC2=O OLGWXCQXRSSQPO-UHFFFAOYSA-N 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dairy Products (AREA)
Abstract
本发明涉及营养组合物,它含有蛋白质、脂肪和碳水化合物;以及a.选自下列的核苷酸组分:核酸、核酸衍生物、核苷酸、多磷酸核苷、多核苷酸、核苷、核糖、脱氧核糖和多磷酸二核苷(NpxN);以及b.分子量在200至20.000道尔顿之间的、带负电荷的、非蛋白质性多糖或复合糖组分。本发明的营养组合物特别适于喂养婴儿,因为它模拟了人乳的保护作用,特别是抵抗过敏和感染的保护作用。
Description
技术领域
本发明涉及喂养婴儿用的营养组合物及其用途,所述营养组合物含有脂肪、蛋白质、碳水化合物、核苷酸组分。
背景技术
母乳喂养最适宜于支持婴儿的发育并保护其抵抗感染和过敏。然而,并不是所有的婴儿都能够接受人乳。因此,提供模拟人乳功能的婴儿配方食品(infant formula)一直是人们努力的方向。婴儿配方食品除了需要与人乳的组成相似以外,还特别需要模拟人乳的保护作用,尤其是抵抗过敏和感染的保护作用。
发明内容
本发明人已经认识到核苷酸的分子结构以及电荷密度是决定核苷酸组分——特别是核苷酸——的生物活性的一个重要因素。已发现通过将核苷酸组分与带负电荷的非蛋白质组分结合可显著增强营养配方中核苷酸组分的生物活性效果。
因此,本发明提供一种营养组合物,它含有一种核苷酸组分,以及一种分子量在200至20.000道尔顿之间的、带负电荷的、非蛋白质性多糖或复合糖组分(以下称为NCC)。
本发明的营养组合物在以下方面特别有效:
·促进免疫细胞增殖,促进T-淋巴细胞亚群的发育并增强抗体应答;
·刺激新生儿免疫系统的发育;
·刺激新生儿神经系统的发育;
·刺激术后或病后新生儿的发育及胃肠道的修复
·调节肠道区系,刺激长链多不饱和脂肪酸的合成
·提供抗感染、抗细菌/病毒作用
无意于囿于理论,认为活性得以提高是由于NCC与核苷酸组分之间的相互作用——例如通过氢桥和盐桥,从而使带负电荷的核苷酸组分更好地提供并递送到上皮细胞。核苷酸的生物活性分子阴离子电荷被压缩,并且电荷的分子分布得到有益的改变。
本发明的营养组合物可通过将核苷酸组分和NCC与二价阳离子——优选钙和/或锌离子——结合而得以进一步改进。阳离子在液体环境(例如肠道)中通过形成氢/盐桥提高核苷酸组分与NCC之间的邻近度(proximity),从而进一步增强NCC与核苷酸组分之间的相互作用。
具体实施方式
本发明提供一种营养组合物,它含有蛋白质、脂肪和碳水化合物,以及选自下列的核苷酸组分:核酸、核酸衍生物、核苷酸、多磷酸核苷、多核苷酸、核苷、核糖、脱氧核糖和多磷酸二核苷(NpxN),以及分子量在200至20.000道尔顿之间的、带负电荷的、非蛋白质性多糖或复合糖组分。
核苷酸组分
本发明的组合物含有一种选自下列的核苷酸组分:核酸、核酸衍生物、核苷酸、多磷酸核苷、多核苷酸、核苷、核糖、脱氧核糖和多磷酸二核苷(NpxN)。
核酸通常为杂环嘧啶碱基胞嘧啶、胸腺嘧啶、尿苷和衍生物,例如假尿苷、二氢尿苷(dihyderouridine)、胸腺嘧啶核苷、4-硫尿苷、3-甲基胞苷、N-乙酰基胞苷、赖胞苷;以及嘌呤碱基腺嘌呤、鸟苷和衍生物,例如1-甲基腺苷、N6-异戊烯基腺苷、肌苷、N7-甲基鸟苷、N2-二甲基鸟苷和怀俄苷。核苷——例如N-糖苷——为嘧啶或嘌呤碱基复合糖。优选的核苷酸为核苷的磷酸酯,它们为寡核苷酸或多核苷酸形式的单体或聚合物。对于本申请而言,尤其是源于动物奶、动物和植物组织、酵母、双歧杆菌和乳酸杆菌以及合成分子的脱氧核糖核酸、核糖核酸、转运核糖核酸和核糖体的水解产物为适合的原料源。(Biochemistry,Donald Voet and Judith G.Voet,John Wiley andSons,Inc NY,第二版,第28章,第849页)
优选地,本发明组合物含有至少一种、优选至少两种、更优选至少三种选自下列的核苷酸:胞苷一磷酸(CMP)、鸟苷一磷酸(GMP)、腺苷一磷酸(AMP)、尿苷一磷酸(UMP)和肌苷一磷酸(IMP)。
在另一个优选的实施方案中,本发明的组合物含有核糖——优选D-核糖——作为核苷酸组分。D(-)核糖是一种可以结晶产品的形式购得的戊糖。核糖是核酸的主要成分。本发明的组合物优选地含有以产品的干重计0.01wt.%至50wt.%的核糖,更优选0.05wt.%至10wt.%,进一步更优选0.5.至10wt.%。
本发明的组合物每100克干重优选含有5至100mg的核苷和/或5至100mg的核苷酸,更优选在5至50mg之间。核苷酸和/或核苷进一步刺激免疫系统,与本发明组合物的NCC协同作用。
带负电荷的组分(NCC)
本发明组合物含有一种分子量在200至20.000道尔顿之间的、带负电荷的、非蛋白质性多糖和复合糖组分(NCC)。
NCC在pH为7的水中带负电荷。负电荷优选由羧基、磷酸酯基和/或硫酸酯基提供,最优选由羧基提供。优选地,NCC的MW在1000至10.000道尔顿之间。本发明营养组合物中的核苷酸组分/NCC的重量比优选在100至0.1之间。
优选地,NCC选自鞘糖脂、酸性寡糖和唾液酸化的寡糖。唾液酸化的寡糖优选为唾液酸乳糖和/或双唾液酸-乳新四糖(disialo-lactoneotertaose,DS-LNT)。鞘糖脂通常为带有与神经酰胺直接相连的单糖的化合物。
优选地,NCC含有神经节苷脂(一种鞘糖脂)。神经节苷脂通常为高度复杂的寡糖基神经酰胺,除了葡萄糖、半乳糖和半乳糖胺以外,它还含有一个或多个唾液酸基(N-酰基、尤其是乙酰基,缩写为“NANA”的神经氨酸的衍生物)。对于本申请而言,尤其是酪乳、蛋黄卵磷脂为适合的神经节苷脂原料源。(Biochemistry,Donald Voet and JudithG.Voet,John Wiley and Sons,Inc NY,第二版,第23章)。因此本发明的组合物优选含有蛋黄卵磷脂和/或酪乳。
在特别优选的实施方案中,本发明的组合物含有选自GM3、GM1和GD1的神经节苷脂。
在另一个优选的实施方案中,本发明的组合物含有硫酸鞘糖脂(sulfoglycosphingolipid)作为NCC。硫酸鞘糖脂是硫酸酯基连接到半乳糖基部分的3位的半乳糖苷神经酰胺和乳糖苷神经酰胺的硫酸酯(通常称为“硫苷脂”或“硫酸脂类(lipid sulfate)”)。
酸性寡糖
本发明组合物优选含有DP为2至100、优选2至60的酸性寡糖。术语酸性寡糖指含有至少一个选自下列的酸性基团的寡糖:N-乙酰基神经氨酸、N-乙醇酰基神经氨酸、游离或酯化的羧酸、硫酸基和磷酸基。酸性寡糖优选含有糖醛酸单元(即糖醛酸聚合物),更优选含有半乳糖醛酸单元。本发明组合物每100g干重优选含有0.1至10g酸性寡糖,更优选每100g干重含有1至6g酸性寡糖。
结构1:聚合酸性寡糖
其中:
R优选选自氢、羟基或酸基,优选羟基;并且R2、R3、R4和R5中的至少一个代表N-乙酰基神经氨酸、N-乙醇酰基神经氨酸、游离或酯化的羧酸、硫酸基和磷酸基,并且其余的R2、R3、R4和R5代表羟基和/或氢。优选地,R2、R3、R4和R5中的一个代表N-乙酰基神经氨酸、N-乙醇酰基神经氨酸、游离或酯化的羧酸、硫酸基或磷酸基,并且其余的代表羟基和/或氢。更优选地,R2、R3、R4和R5中的一个代表游离或酯化的羧酸,并且其余的R2、R3、R4和R5代表羟基和/或氢;并且n是一个整数且指己糖单元的数目(还可参见以下聚合度部分),所述己糖单元可为任何己糖单元。适合的n为1-5000之间的整数。优选地,己糖单元为糖醛酸单元。
最优选地,R1、R2和R3代表羟基,R4代表氢,R5代表羧酸,n为1至250之间、优选1至10之间的任何数,并且己糖单元为半乳糖醛酸。
本发明方法中所使用的优选的酸性寡糖的检测、测量和分析已在申请人更早的、涉及酸性寡糖的专利申请,即WO 0/160378中给出。
优选地,酸性寡糖具有一个、优选两个末端糖醛酸单元,所述糖醛酸单元可为游离形式或酯化形式。优选的末端糖醛酸单元选自:半乳糖醛酸、葡糖醛酸、古洛糖醛酸、艾杜糖醛酸、甘露糖醛酸、riburonicacid和alturonic acid。这些单元可为游离形式或酯化形式。在一个更优选的实施方案中,末端己糖单元具有双键,该双键优选位于末端己糖单元的C4和C5位之间。优选地,一个末端己糖单元含有双键。末端己糖(例如糖醛酸)优选具有图2结构。
图2:优选的末端己糖酸基
其中:
R优选选自氢、羟基或酸基,优选羟基(参见上述);并且R2、R3、R4和R5中的至少一个代表N-乙酰基神经氨酸、N-乙醇酰基神经氨酸、游离或酯化的羧酸、硫酸基和磷酸基,并且其余的R2、R3、R4和R5代表羟基和/或氢。优选地,R2、R3、R4和R 5中的一个代表N-乙酰基神经氨酸、N-乙醇酰基神经氨酸、游离或酯化的羧酸、硫酸基和磷酸基,并且其余的R2、R3、R4和R5代表羟基和/或氢。更优选地,R2、R3、R4和R5中的一个代表游离或酯化的羧酸,并且其余的R2、R3、R4和R5代表羟基和/或氢;并且n是一个整数且指己糖单元的数目(还可参见以下聚合度部分),所述己糖单元可为任何己糖单元。适合的n为1-100之间的整数,代表己糖单元的数目,所述己糖单元优选为糖醛酸,更优选为半乳糖醛酸。这些单元上的羧酸基可为游离形式或(部分)酯化的形式,并且优选至少部分甲基化。
最优选地,R2和R3代表羟基,R4代表氢并且R5代表游离或酯化的羧酸。
本发明中使用的酸性寡糖优选由果胶、果胶酸盐、藻酸盐、软骨素(chondroitine)、透明质酸、肝素(heparine)、类肝素(heparane)、细菌碳水化合物、唾液酸多糖(sialoglycan)、岩藻多糖、岩藻寡糖(fucooligosaccharide)或角叉藻多糖制备,更优选由果胶和/或藻酸盐制备。优选使用通常可生化解聚的果胶。最优选使用可通过果胶裂合酶解聚的果胶。
二价阳离子
本发明的营养组合物优选含有二价阳离子。二价阳离子改善核苷酸组分与NCC之间的邻近度,进而改变电荷密度并提高生物活性。本发明组合物优选含有至少一种选自下列的二价阳离子:镁、钙、铁、铬、锰、钼、铜和锌。优选地,本发明组合物至少含有钙和/或锌。
锌有利地包括在本发明的组合物中。锌在与本发明的NCC结合后提高核苷酸的生物活性,并且它还是生长和免疫功能发育所必需的微量营养物,对于婴儿而言尤为如此。缺乏锌将削弱整体免疫功能以及对感染的抵抗力。因此,本发明的组合物有利地含有锌,优选每100g干重的本发明组合物含有2至100mg的锌,更优选每100g干重的本发明组合物含有3至25mg的锌。锌的重量以元素锌计。
在另一个优选的实施方案中,本发明的组合物含有钙以改善电荷的相互作用。钙也是婴儿饮食中所必需的,并因此有利地包括在本发明的组合物中。优选地,本发明的组合物含有以组合物总的干重计重量为150至1000mg的钙。
常量营养物
本发明的组合物可有利地用作婴儿配方食品。婴儿配方食品优选以液体的形式给予至婴儿。术语婴儿包括断乳婴儿和刚学步的婴孩。
在一个优选实施方案中,本发明涉及提供婴儿饮食的常量营养物的营养组合物。因此,本发明组合物优选含有30至60en%脂类;5至15en%蛋白质;以及25至65en%碳水化合物。优选地,本发明组合物含有43至53en%脂类;7至11en%蛋白质;以及43至53en%碳水化合物(en%是能量百分比的缩写,代表各成分对制剂总热值的相对贡献量)。本申请中的术语“蛋白质”或蛋白质组分是蛋白质、多肽、肽和氨基酸的总和。本发明组合物中的碳水化合物优选主要由乳糖提供,即优选地,至少75wt.%、优选至少90wt.%的总的可消化的碳水化合物由乳糖提供。
必需的脂肪酸含量
本发明组合物优选含有以总脂肪酸计至少10wt.%、优选11至20wt.%、更优选12至15wt.%的亚油酸(LA)。本发明组合物优选含有以总脂肪酸计至少1wt.%、优选1.5至4wt.%、更优选2至2.5wt.%的α-亚油酸(ALA)。为降低肠压,LA/ALA的重量比优选在2至10、优选5至7.5之间。本发明的组合物优选包括以总脂肪酸计0.05至5wt%、优选0.1至1wt.%的γ-亚油酸(GLA)。优选地,本发明组合物含有0.05至5wt%、更优选0.1至1wt.%的steraidonic acid(STA)。
长链多不饱和脂肪酸含量
本发明组合物优选含有至少一种以总脂肪酸计含量超过0.1wt.%的、具有20或22个碳原子的、选自下列的长链多不饱和脂肪酸(LCPUFA):二十二碳六烯酸(DHA)、花生四烯酸(AA)和二十碳五烯酸(EPA)。优选地,本发明组合物含有以总脂肪酸计含量超过0.1wt.%的DHA;以及以总脂肪酸计含量超过0.1wt.%的AA。
优选地,这类LCPUFA中的至少一种以组合物的总脂肪酸的含量计,以0.15至1wt.%之间的量包括在组合物中。优选地,这些LCPUFA中的至少两种以组合物的总脂肪酸的含量计,以0.15至1wt.%之间的量存在。优选地,组合物含有AA和DHA,更优选含有AA、DHA和EPA。
AA的含量优选不超过总脂肪酸的5wt.%,更优选不超过1wt.%,最优选在0.1至0.6wt.%之间。在本发明的组合物中,有利地添加EPA和/或DHA以平衡AA的作用,例如以降低AA代谢物的可能的促炎作用。过量的AA代谢物可能导致炎症。因此,本发明组合物优选含有AA、EPA和/或DHA,其中AA/DHA的重量比优选高于0.25,优选高于0.5,更优选高于1。AA/DHA比优选低于25,优选低于10。AA/EPA的重量比优选在1至100之间,更优选在5至20之间。EPA/DHA的重量比优选为1或更低,更优选低于0.5。
在一个优选实施方案中,由于需要尽可能地模拟人乳,因此LCPUFA的含量不超过总脂肪酸的3wt.%。出于相同的原因,本发明组合物优选每100g脂肪酸含有低于1g的Ω-3 LCPUFA,更优选每100g脂肪酸含有0.1至0.75g。Ω-6 LCPUFA的含量优选每100g脂肪酸不超过2g,并且优选每100g脂肪酸含有0.1至0.75g。
LCPUFA和其他脂肪酸可以以游离脂肪酸的形式、以甘油三酸酯的形式、以磷脂形式,或以上述形式中一种或多种的混合形式提供。本发明组合物有利地包括磷脂形式的AA和DHA中的至少一种,因为它们可降低肠炎病症的发生。本发明组合物优选每g总脂肪含有0.1至5mg磷脂形式的AA以及每g总脂肪0.1至5mg的磷脂形式的DHA。优选地,AA和/或DHA至少部分地以磷脂酰胆碱(PC)和/或磷脂酰乙醇胺(PE)的形式存在,例如含有PE和/或PC的AA和/或DHA。
寡糖
本发明的组合物优选含有聚合度(DP)在2至100之间的不可消化的寡糖。据信寡糖对于提供适宜的肠环境以改善结合的核苷酸组分和NCC的提供及其电荷密度非常重要。不可消化的寡糖降低肠环境的pH,提高核苷酸的生物活性。优选地,本发明组合物每100g干重含有0.1至12g、优选3至8g、更优选5至7.5g不可消化的寡糖。粉末在液体中复原并向婴儿给予液体配方后,这些量的不可消化的寡糖提供所需的作用而不引起肠不适。适合的不可消化的寡糖在肠中在人类上消化道(小肠和胃)中存在的酸或消化酶的作用下不消化或仅部分消化,但可通过人类的肠内微生物区系发酵。寡糖优选为水溶性的(每升水中的溶解度超过1g寡糖)。本发明的寡糖的平均DP优选低于40,更优选低于20。最优地,本发明组合物含有2至12g、DP为2至60、更优选DP为2至10的寡糖(即DP为2、3、4、5、6、7、8、9和10的寡糖的总重量)。
根据另一个实施方案,本发明组合物中的至少一种寡糖选自菊粉、果寡糖、不可消化的糊精、半乳寡糖(galactooligosaccharide)(包括反式半乳寡糖)、木寡糖(xylooligosaccharide)、阿拉伯寡糖(arabinooligosaccharide)、葡萄寡糖(glucooligosaccharide)、甘露寡糖(mannooligo-saccharide)、乳-N-新四糖(lacto-N-neotetraose)、岩藻寡糖(fucooligosaccharide)(含有至少一个岩藻糖单元)、酸性寡糖(例如糖醛酸寡糖,例如果胶寡糖)及其混合物。
优选地,本发明组合物含有菊粉和果寡糖中的至少一种,以及半乳寡糖(包括反式半乳寡糖)和果胶水解产物中的至少一种。在一个特别优选的实施方案中,本发明组合物含有2至12g、DP为2至10的寡糖和β-连接的半乳糖以及葡萄糖糖类,更优选反式半乳寡糖(即[gal]n-glu,其中n为2至10)。在一个特别优选的实施方案中,本发明组合物含有反式半乳寡糖(即[gal]n-glu,其中n为2至10),果胶水解产物,以及选自果寡糖和菊粉中的至少一种。本发明的寡糖优选源于动物奶、或为源于动物奶的寡糖的混合物或岩藻糖基化的寡糖(含有至少一个岩藻糖单元的寡糖)。
为了进一步改善整个结肠区域的肠的成熟,优选地,本发明组合物中至少10wt.%的寡糖具有2至5(即2、3、4和/或5)的DP并且至少5wt.%具有10至100的DP。优选至少50wt.%、更优选至少75wt.%的寡糖具有2至10(即2、3、4、5、6、7、8、9和/或10)的DP,因为据信它们在整个结肠的回肠以及近侧和中间部位起作用,并且因为这将降低达到预期效果所需的掺入组合物中的寡糖的重量百分比。
优选地,下列重量比均大于1:
(DP为2至5的寡糖):(DP为6至9的寡糖);以及
(DP为10至100的寡糖):(DP为6至9的寡糖)。优选地,上述两重量比均大于2,更优选大于5。
本发明组合物每100g干重优选含有0.5至10g、更优选1至5g的、DP在2至10之间的半乳寡糖。优选的半乳寡糖为反式半乳寡糖,因为这将最大限度地模拟人乳中的寡糖。本发明中每100g干重的组合物优选含有0.5至10g、更优选1至5g的、DP在10至60之间的果多糖(fructopolysaccharide)。术语“果多糖”指含有具有至少10个β-连接的果糖单元的链的多糖碳水化合物。
液体
本发明的营养组合物优选为粉末或液体形式或片剂形式,其中所述片剂的重量为5至25g。优选地,本发明组合物以粉末形式提供,因为这将延长贮存期限。本发明组合物优选以液体形式口服。给予本发明组合物前,优选将其与液体——优选水——混合。
粪便不规律(例如粪便发硬、粪便量不足、腹泻)是许多婴孩和接受流食的生病个体遇到的一个主要问题。已发现通过给予摩尔渗透压浓度为50至500mOsm/kg、更优选100至400mOsm/kg、最优选220至300mOsm/kg的液体形式的本发明组合物可缓解粪便问题。
考虑到上述腹泻问题,同样重要的是流食应不具备过大的热量密度(caloric density),因为这将引起高肠压。然而,配方食品需要为喂养婴儿提供足够的热量。因此,流食优选具有0.5至0.9千卡/ml、优选0.6至0.8千卡/ml的热量密度。
应用
本发明组合物有利地给予至0到2岁的婴儿。本发明组合物还可有利地用于满足早产儿(妊娠37周前出生的婴儿)营养需求的方法。在一个优选的实施方案中,本发明提供了一种喂养0至30天婴儿的方法。
本发明组合物可有利地用于治疗或预防其中相关的免疫系统和/或肠屏障功能不成熟为疾病进程发展基础的疾病。因此本发明组合物可有利地用于治疗或预防腹泻或过敏,特别是针对0至2岁的婴儿。具体而言,本发明组合物适于治疗和/或预防变应性鼻炎、变应性结膜炎、变应性皮炎、特应性皮炎和/或食物过敏。在一个优选的实施方案中,本发明方法提供用于治疗和/或预防感染的方法,所述方法包括给予本发明的组合物。
本发明通过以下实施例进一步予以说明:
实施例1:婴儿营养物
液体婴儿营养物,将13.9g粉末与水混合得到100ml最终产物,所述液体产物每100ml包括:
能量: 66千卡
蛋白质: 8en%
1.3g(含有0.6g酪蛋白;0.8g乳清;0.072g L-精氨酸)
可消化的碳水化合物: 44en%
7.4g(含有7.3g乳糖)
脂肪: 48en%
3.5g(含有0.41g亚油酸;0.08g α-亚油酸;0.012g花生四烯酸;0.002g二十碳五烯酸;0.006g二十二碳六烯酸;1.4g油酸;)
纤维:
0.8g(含有0.05g果多糖(Raftiline HPTM,Orafti,Tienen,比利时);0.55g反式半乳寡糖(Vivinal-GOSTM(Borculo DomoIngredients,荷兰);0.20g果胶水解产物,按照EP1373543的实施例1中所述的制备。
核苷酸组分:
0.89mg 胞苷-5-一磷酸;
0.55mg 尿苷-5-一磷酸;
0.82mg 腺苷-5-一磷酸;
0.20mg 鸟苷-5-一磷酸;
0.34mg 肌苷-5-一磷酸。
NCC:
5mg GM3,50mg果胶衍生的、DP为5至50的寡糖以及20mg唾液酸乳糖
钙:
53mg 钙
锌:
0.8mg 锌
摩尔渗透压浓度:300mOsmol/l
组合物还含有胆碱(6mg/100ml)和牛磺酸(6.3mg/100ml);以及含量依照婴儿配方奶粉国际准则的矿物质、微量元素和维生素。
实施例2:
实施例1的组合物,其中核苷酸组分用多磷酸二核苷(NpxN)Gp4G代替。
实施例3:
实施例1的组合物,其中核苷酸组分为DNA/RNA低聚物提取物。
实施例4
实施例1的组合物,含有以组合物总的干重计1wt.%的D-核糖。
Claims (14)
1.营养组合物,含有蛋白质、脂肪和碳水化合物;以及
a.选自下列的核苷酸组分:核酸、核酸衍生物、核苷酸、多磷酸核苷、多核苷酸、核苷、核糖、脱氧核糖和多磷酸二核苷(NpxN);以及
b.分子量在200至20.000道尔顿之间的、带负电荷的、非蛋白质性多糖或复合糖组分。
2.权利要求1的营养组合物,其中组分b具有1000至10.000道尔顿的分子量。
3.权利要求1或2的营养组合物,其中营养组合物含有5至15en%蛋白质;30至60en%脂肪;以及25至65en%碳水化合物。
4.前述权利要求中任一项的营养组合物,其中营养组合物每100g干重含有5至100mg核苷酸和/或5至100mg核苷。
5.权利要求1-3中任一项的营养组合物,其中核苷酸组分为核糖。
6.前述权利要求中任一项的营养组合物,每100g干重的该组合物分别含有150至1000mg钙和/或2至100mg锌。
7.前述权利要求中任一项的营养组合物,其中带负电荷的组分选自酸性寡糖和神经节苷脂。
8.前述权利要求中任一项的营养组合物,其中带负电荷的组分为DP在2至100之间的多聚半乳糖醛酸,优选果胶水解产物。
9.权利要求1-7中任一项的营养组合物,其中带负电荷的组分为神经节苷脂。
10.用作药物的前述任一项权利要求的营养组合物。
11.权利要求1-9中任一项的营养组合物用于制造向婴儿提供营养物的方法中所使用的组合物的用途,所述方法包括给予所述营养组合物。
12.权利要求1-9中任一项所定义的营养组合物用于制造给予至哺乳动物以治疗和/或预防炎症、腹泻、湿疹和/或特应性皮炎的组合物的用途。
13.权利要求12的用途,其中所述炎症为过敏。
14.权利要求12或13中任一项的用途,其中哺乳动物为人类婴儿。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04019856.6 | 2004-08-20 | ||
EP04019856A EP1634599A1 (en) | 2004-08-20 | 2004-08-20 | Iimmune stimulatory infant nutrition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101039686A true CN101039686A (zh) | 2007-09-19 |
Family
ID=34926246
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910225789XA Expired - Fee Related CN101766228B (zh) | 2004-08-20 | 2005-08-19 | 刺激免疫的婴儿营养品 |
CNA2005800281714A Pending CN101048167A (zh) | 2004-08-20 | 2005-08-19 | 刺激免疫的婴儿营养品 |
CNA2005800351685A Pending CN101039686A (zh) | 2004-08-20 | 2005-08-22 | 免疫刺激婴儿营养物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910225789XA Expired - Fee Related CN101766228B (zh) | 2004-08-20 | 2005-08-19 | 刺激免疫的婴儿营养品 |
CNA2005800281714A Pending CN101048167A (zh) | 2004-08-20 | 2005-08-19 | 刺激免疫的婴儿营养品 |
Country Status (15)
Country | Link |
---|---|
US (3) | US8114441B2 (zh) |
EP (3) | EP1634599A1 (zh) |
JP (2) | JP4965444B2 (zh) |
CN (3) | CN101766228B (zh) |
AT (1) | ATE427112T1 (zh) |
AU (2) | AU2005274266B2 (zh) |
BR (2) | BRPI0514526A (zh) |
CA (2) | CA2576042C (zh) |
DE (1) | DE602005013679D1 (zh) |
ES (1) | ES2322380T3 (zh) |
NZ (2) | NZ553248A (zh) |
PL (1) | PL1781307T3 (zh) |
RU (2) | RU2426549C2 (zh) |
UA (1) | UA88918C2 (zh) |
WO (2) | WO2006018314A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101978841A (zh) * | 2010-08-31 | 2011-02-23 | 浙江贝因美科工贸股份有限公司 | 一种抗蛋白过敏及营养婴儿配方奶粉 |
WO2022166641A1 (zh) * | 2021-02-02 | 2022-08-11 | 陈玉松 | 核苷酸的新用途 |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1723951A1 (en) * | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
PT1629850E (pt) | 2004-08-24 | 2007-08-14 | Nutricia Nv | Composição nutricional que compreende a administração de oligossacarídeos indigeríveis |
US20060210697A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Infant formula composition |
US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
US20060210524A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin care composition |
US7749545B2 (en) | 2005-03-18 | 2010-07-06 | Sakura Properties, Llc | Fucoidan compositions and methods for dietary and nutritional supplements |
EP1888081B1 (en) | 2005-05-23 | 2016-12-28 | Massachusetts Institute of Technology | Compositions containing pufa and methods of use thereof |
EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
WO2008054192A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
ES2366034T3 (es) * | 2005-12-23 | 2011-10-14 | N.V. Nutricia | Composición que comprende ácidos grasos poliinsaturados, proteínas, manganeso y/o molibdeno y nucleósidos/nucleótidos para el tratamiento de la demencia. |
RU2444210C2 (ru) * | 2005-12-23 | 2012-03-10 | Н.В. Нютрисиа | Питательные композиции для младенцев, предназначенные для предупреждения ожирения |
WO2007096148A1 (en) * | 2006-02-23 | 2007-08-30 | Lipid Nutrition B.V. | Immunoregulation |
JP4610499B2 (ja) * | 2006-02-27 | 2011-01-12 | ポーラ化成工業株式会社 | 食品組成物 |
WO2007114683A1 (en) | 2006-03-30 | 2007-10-11 | N.V. Nutricia | Milk oligosaccharides for stimulating the immune system |
CN101795579A (zh) | 2006-08-04 | 2010-08-04 | Shs国际有限公司 | 无蛋白配方 |
US20080145506A1 (en) * | 2006-12-18 | 2008-06-19 | Bodybio, Inc. | Food compositions and products containing balanced ratio of essential fatty acids |
WO2008111832A1 (en) * | 2007-03-13 | 2008-09-18 | N.V. Nutricia | Method of improving skills with a composition comprising non-digestible saccharide |
WO2008115046A1 (en) * | 2007-03-22 | 2008-09-25 | N.V. Nutricia | Cereal-based infant nutrition with fibre |
WO2008144145A1 (en) * | 2007-05-18 | 2008-11-27 | Mead Johnson Nutrition Company | Acidified liquid human milk supplement |
EP3263120A1 (en) * | 2007-09-17 | 2018-01-03 | N.V. Nutricia | Nutritional formulation with high energy content |
US10251899B2 (en) * | 2007-10-08 | 2019-04-09 | Mead Johnson Nutrition Company | Method for improving stool characteristics in infants |
US20110009349A1 (en) | 2007-10-19 | 2011-01-13 | Fonterra Co-Operative Group Limited | Methods of maintaining or increasing growth or cognitive development |
MX2010004820A (es) * | 2007-11-01 | 2010-08-10 | Enzymotec Ltd | Mezcla lipidica para nutricion infantil. |
WO2009057994A1 (en) * | 2007-11-02 | 2009-05-07 | N.V. Nutricia | Unit dosage for brain health |
WO2009075564A1 (en) * | 2007-12-10 | 2009-06-18 | N.V. Nutricia | Paediatric fibre mixture |
JP5979816B2 (ja) * | 2008-01-04 | 2016-08-31 | ネステク ソシエテ アノニム | 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用 |
EP2130440A1 (en) * | 2008-06-06 | 2009-12-09 | N.V. Nutricia | Inhibiting E. sakazakii growth |
CA2749254A1 (en) * | 2009-01-19 | 2010-07-22 | Catherine Mace | Nutritional composition for infants |
WO2010110649A1 (en) * | 2009-03-24 | 2010-09-30 | N.V. Nutricia | Stage 1 and stage 2 infant formula |
WO2010147456A1 (en) * | 2009-06-19 | 2010-12-23 | N.V. Nutricia | Inhibition of nfk-b mediated virus replication with specific oligosaccharides |
CA2787318A1 (en) * | 2010-01-21 | 2011-07-28 | Paul Bradley Addis | Composition for perinatal and neonatal stroke |
NZ623342A (en) | 2010-04-26 | 2014-12-24 | Enzymotec Ltd | Methods and lipid compositions for promoting development of gut flora |
JP5996837B2 (ja) * | 2010-05-28 | 2016-09-21 | 小林製薬株式会社 | インフルエンザウイルスの感染抑制剤 |
WO2012044155A1 (en) * | 2010-09-28 | 2012-04-05 | N.V. Nutricia | Fat composition for programming immune response |
EP2465507A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
DK2498628T3 (da) | 2010-12-29 | 2014-06-23 | Abbott Lab | Produkter til at formindske forekomsten af nekrotiserende enterocolitis, kolik og korttarmsyndrom hos et spædbarn, en tumling eller et barn |
ES2804258T3 (es) | 2010-12-31 | 2021-02-05 | Abbott Lab | Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios |
EP2658547A1 (en) | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
NZ612472A (en) * | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
MX355424B (es) | 2010-12-31 | 2018-04-18 | Abbott Lab | Oligosacáridos de leche humana para modular la inflamación. |
CA2822664C (en) | 2010-12-31 | 2021-07-20 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
MX355780B (es) | 2010-12-31 | 2018-04-30 | Abbott Lab | Fórmula pediátrica sintética para estimular células nerviosas entéricas en el tracto gastrointestinal. |
CA2822495C (en) | 2010-12-31 | 2020-12-22 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
US8795746B2 (en) * | 2011-02-16 | 2014-08-05 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic use of mucin glycans |
FI124323B (fi) | 2011-02-18 | 2014-06-30 | Valio Oy | Maitopohjainen tuote ja menetelmä sen valmistamiseksi |
JP5837315B2 (ja) * | 2011-03-25 | 2015-12-24 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
WO2012133198A1 (ja) * | 2011-03-25 | 2012-10-04 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
WO2012177118A1 (en) | 2011-06-22 | 2012-12-27 | N.V. Nutricia | Method for reducing the occurrence of infection in young children |
BR112014001472A2 (pt) | 2011-07-22 | 2017-02-21 | Abbott Lab | galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal |
BR112014004772A2 (pt) | 2011-08-29 | 2017-03-21 | Abbott Lab | oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal |
PL2988617T3 (pl) | 2013-03-27 | 2024-02-19 | Nutritional Growth Solutions Ltd | Suplement odżywczy do poprawy wzrostu |
US20140328970A1 (en) * | 2013-05-03 | 2014-11-06 | Mead Johnson Nutrition Company | Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof |
DE202013008190U1 (de) | 2013-09-17 | 2013-12-05 | Pg Naturpharma Gmbh | Zubereitung und deren Verwendung bei atopischer Dermatitis |
EP2857410A1 (en) * | 2013-10-04 | 2015-04-08 | Jennewein Biotechnologie GmbH | Process for purification of 2´-fucosyllactose using simulated moving bed chromatography |
RU2697650C1 (ru) * | 2013-11-15 | 2019-08-16 | Сосьете Де Продюи Нестле С.А. | Композиции для профилактики или лечения аллергий у младенцев, рожденных или вскармливаемых матерями несекреторного типа, путем обеспечения фукозилированными олигосахаридами, в частности среди младенцев, подверженных риску или рожденных с помощью кесарева сечения |
US20150157048A1 (en) * | 2013-12-11 | 2015-06-11 | Mead Johnson Nutrition Company | Nutritional compositions containing stearidonic acid and uses thereof |
WO2015154257A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and, nutritional systems comprising them |
WO2015154263A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154260A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
WO2015154254A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154251A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
WO2015154265A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154256A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and,nutritional systems comprising them |
WO2015154259A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
MY186844A (en) | 2014-07-09 | 2021-08-25 | Cadena Bio Inc | Oligosaccharide compositions and methods for producing thereof |
FR3029114B1 (fr) * | 2014-12-01 | 2017-01-13 | United Pharmaceuticals | Composition nutritionnelle infantile dans le traitement de la dermatite atopique et de ses symptomes |
JP6722697B2 (ja) | 2015-01-26 | 2020-07-15 | カデナ・バイオ・インコーポレイテッド | 動物飼料として使用するためのオリゴ糖組成物及びその生成方法 |
PT3354282T (pt) | 2015-01-26 | 2021-03-18 | Kaleido Biosciences Inc | Produtos terapêuticos de glicanos e seus métodos relacionados |
CA2983236A1 (en) * | 2015-04-23 | 2016-10-27 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
US10582714B2 (en) | 2015-07-10 | 2020-03-10 | Mead Johnson Nutrition Company | Nutritional compositions and methods for promoting cognitive development |
CN105231461A (zh) * | 2015-10-30 | 2016-01-13 | 中营康园(北京)科技有限公司 | 一种提高机体免疫力的营养组合物及其应用 |
ES2638195B1 (es) | 2016-04-18 | 2018-08-02 | Bioiberica, S.A. | Composiciones para la piel |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
US11849747B1 (en) | 2019-06-24 | 2023-12-26 | PBM Nutritionals, LLC | Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61192245A (ja) * | 1985-02-21 | 1986-08-26 | Snow Brand Milk Prod Co Ltd | アルギニン配合粉乳 |
ES2007350A6 (es) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion. |
AU769645B2 (en) | 1987-05-29 | 2004-01-29 | Abbott Laboratories | Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation |
CA2053933C (en) | 1990-10-24 | 2002-09-10 | Norman A. Greenberg | Nutritional composition comprising hydrolysed soluble fiber |
KR100321543B1 (ko) | 1991-01-24 | 2002-09-12 | 마르텍 코포레이션 | 미생물-기원오일혼합물및이의용도 |
US5472952A (en) | 1993-03-18 | 1995-12-05 | Bristol-Myers Squibb Company | Partially hydrolyzed pectin in nutritional compositions |
DE4344342C2 (de) * | 1993-12-23 | 1996-08-08 | Milupa Ag | Molkenprotein-dominante Säuglingsnahrung |
JP3419897B2 (ja) * | 1994-07-22 | 2003-06-23 | 明治乳業株式会社 | 低アレルギー性調製乳 |
JP4034364B2 (ja) * | 1994-10-11 | 2008-01-16 | 雪印乳業株式会社 | 抗アレルギー剤 |
ES2123903T5 (es) * | 1995-08-04 | 2011-02-22 | N.V. Nutricia | Composición nutritiva conteniendo fibra. |
US5792501A (en) * | 1996-04-15 | 1998-08-11 | The Iams Company | Queen's milk replacer |
US5780081A (en) * | 1996-10-28 | 1998-07-14 | Nestec S.A. | Fortification of food with calcium and process of making |
JPH10262607A (ja) * | 1997-03-28 | 1998-10-06 | Snow Brand Milk Prod Co Ltd | 乳幼児用栄養組成物 |
DK0996732T3 (da) | 1997-04-11 | 2005-10-17 | Calgene Llc | Fremgangsmåder og sammensætninger til syntese af langkædede polyumættede fedtsyrer i planter |
US6288116B1 (en) * | 1998-05-13 | 2001-09-11 | Novartis Nutrition Ag | Method of administration of a nutritional product to a person having renal failure |
FR2781673B1 (fr) * | 1998-07-28 | 2001-09-28 | Univ Picardie | Utilisation d'un glucuronane en tant qu'agent immunostimulant, procede de preparation |
DE19836339B4 (de) * | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
US6245379B1 (en) * | 1998-09-30 | 2001-06-12 | The Iams Company | Method of administering a milk substitute to critical care animals |
GB9923048D0 (en) * | 1999-09-29 | 1999-12-01 | Nestle Sa | Composition comprising casein protein and whey protein |
US6777391B1 (en) * | 1999-04-29 | 2004-08-17 | Nestec S.A. | Composition for an infant formula having a low threonine content |
DE19958985A1 (de) * | 1999-12-07 | 2001-06-13 | Nutricia Nv | Oligosaccharidmischung |
DE10006989A1 (de) | 2000-02-16 | 2001-08-23 | Nutricia Nv | Antiadhäsive Kohlenhydratmischung |
US6630452B2 (en) * | 2000-02-17 | 2003-10-07 | Wyeth | Nutritional formulation containing prebiotic substances |
US20040143013A1 (en) | 2000-02-28 | 2004-07-22 | Bristol-Myers Squibb Company | Use of docosahexaenoic acid and arachidonic acid enhancing the growth of preterm infants |
US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
DE10057976B4 (de) | 2000-11-22 | 2005-02-03 | Südzucker AG Mannheim/Ochsenfurt | Verfahren zur Herstellung von Pektinhydrolyseprodukten |
US6511696B2 (en) * | 2000-12-13 | 2003-01-28 | Novartis Nutrition Ag | Infant formula with free amino acids and nucleotides |
US6623954B1 (en) | 2002-05-28 | 2003-09-23 | Neose Technologies, Inc. | Process for removal of phosphorous from a dairy stream |
DE60327211D1 (de) | 2002-06-28 | 2009-05-28 | Glykos Finland Oy | Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall |
DK1721612T3 (da) | 2003-10-24 | 2009-06-02 | Nutricia Nv | Immunmodulerende oligosaccharider |
-
2004
- 2004-08-20 EP EP04019856A patent/EP1634599A1/en not_active Withdrawn
-
2005
- 2005-08-19 PL PL05777309T patent/PL1781307T3/pl unknown
- 2005-08-19 DE DE602005013679T patent/DE602005013679D1/de active Active
- 2005-08-19 CA CA2576042A patent/CA2576042C/en not_active Expired - Fee Related
- 2005-08-19 JP JP2007526399A patent/JP4965444B2/ja active Active
- 2005-08-19 CN CN200910225789XA patent/CN101766228B/zh not_active Expired - Fee Related
- 2005-08-19 NZ NZ553248A patent/NZ553248A/en not_active IP Right Cessation
- 2005-08-19 EP EP05777309A patent/EP1781307B1/en not_active Revoked
- 2005-08-19 US US11/660,594 patent/US8114441B2/en not_active Expired - Fee Related
- 2005-08-19 BR BRPI0514526-0A patent/BRPI0514526A/pt not_active Application Discontinuation
- 2005-08-19 ES ES05777309T patent/ES2322380T3/es active Active
- 2005-08-19 CN CNA2005800281714A patent/CN101048167A/zh active Pending
- 2005-08-19 UA UAA200702905A patent/UA88918C2/ru unknown
- 2005-08-19 AU AU2005274266A patent/AU2005274266B2/en not_active Ceased
- 2005-08-19 RU RU2007110174/10A patent/RU2426549C2/ru not_active IP Right Cessation
- 2005-08-19 WO PCT/EP2005/008999 patent/WO2006018314A2/en active Application Filing
- 2005-08-19 AT AT05777309T patent/ATE427112T1/de not_active IP Right Cessation
- 2005-08-22 AU AU2005273099A patent/AU2005273099B2/en not_active Ceased
- 2005-08-22 RU RU2007110173/15A patent/RU2404785C2/ru not_active IP Right Cessation
- 2005-08-22 WO PCT/NL2005/000609 patent/WO2006019300A2/en active Application Filing
- 2005-08-22 BR BRPI0514498-1A patent/BRPI0514498A/pt not_active IP Right Cessation
- 2005-08-22 CN CNA2005800351685A patent/CN101039686A/zh active Pending
- 2005-08-22 NZ NZ553299A patent/NZ553299A/en not_active Application Discontinuation
- 2005-08-22 JP JP2007527084A patent/JP2008510697A/ja active Pending
- 2005-08-22 US US11/573,939 patent/US20080125346A1/en not_active Abandoned
- 2005-08-22 CA CA002577698A patent/CA2577698A1/en not_active Abandoned
- 2005-08-22 EP EP05775170A patent/EP1781306A2/en not_active Withdrawn
-
2012
- 2012-01-27 US US13/360,508 patent/US8580316B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101978841A (zh) * | 2010-08-31 | 2011-02-23 | 浙江贝因美科工贸股份有限公司 | 一种抗蛋白过敏及营养婴儿配方奶粉 |
WO2022166641A1 (zh) * | 2021-02-02 | 2022-08-11 | 陈玉松 | 核苷酸的新用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101039686A (zh) | 免疫刺激婴儿营养物 | |
CN1105506C (zh) | 碳水化合物混合物 | |
EP1871181B2 (en) | Nutritional supplement for hiv patients | |
EP2241196B1 (en) | Nutritional supplement comprising oligosaccharides and cysteine for treating HIV | |
CN105639631A (zh) | 含有非活的双歧杆菌和非消化性寡糖的营养物 | |
CN101415408A (zh) | 用于刺激免疫系统的牛奶低聚糖 | |
US20070167397A1 (en) | Methods and compositions for joint lubrication | |
RU2420296C2 (ru) | Композиции, содержащие олигосахариды, для профилактики или лечения инфекций | |
CN110973263A (zh) | 一种含人乳低聚糖的婴幼儿营养组合物 | |
EP1675595A2 (en) | Immunemodulating oligosaccharides | |
CN101945589A (zh) | 用于改善肠道微生物群的非消化性碳水化合物的用途 | |
CN101262783A (zh) | 用于一类hiv病人的营养补充剂 | |
CN102497869A (zh) | 作为具有新功能益处的母乳等同性不可消化低聚糖的岩藻糖基乳糖 | |
EP2453902A1 (en) | Mixture of non-digestible oligosaccharides for stimulating the immune system | |
EP3641566A1 (en) | Methods for increasing growth of beneficial bacteria in the gastrointestinal tract | |
CN101686995A (zh) | Hiv患者肠内菌群的调节 | |
CN1871015A (zh) | 免疫调节性寡糖 | |
CN101693103B (zh) | 肠屏障完整性的改进 | |
CN117715540A (zh) | 用于喂养接受婴儿配方和人母乳的婴儿的婴儿配方 | |
CN1377897A (zh) | 调节血脂的孔石莼多糖及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070919 |